Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results [Yahoo! Finance]
Allakos Inc. (ALLK)
Last allakos inc. earnings: 11/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.allakos.com/investor-relations
Company Research
Source: Yahoo! Finance
for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024. Recent Allakos Events Initiated the randomized, double-blind, placebo-controlled Phase 1 trial of intravenous (IV) AK006 in patients with chronic spontaneous urticaria. Completed dosing in the randomized, double-blind, placebo-controlled subcutaneous (SC) AK006 cohort in healthy volunteers. Reported safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 trial of IV AK006 in healthy volunteers. Presented preclinical data at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress on mast cell inhibition with AK006. Upcoming Allakos Anticipated Milestones Report safety, PK, and PD results from the Phase 1 trial of SC AK006 in healthy volunteers in Q3 2024. Report randomized double-blind, placebo-controlled data from the Phase 1 trial of AK00
Show less
Read more
Impact Snapshot
Event Time:
ALLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLK alerts
High impacting Allakos Inc. news events
Weekly update
A roundup of the hottest topics
ALLK
News
- Kuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmPR Newswire
- All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- Allakos Provides Business Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy VolunteersGlobeNewswire
- Allakos Inc. (NASDAQ: ALLK) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $3.00 price target on the stock.MarketBeat
ALLK
Earnings
- 11/6/24 - Beat
ALLK
Sec Filings
- 12/9/24 - Form 4
- 12/9/24 - Form 4
- 12/6/24 - Form 144
- ALLK's page on the SEC website